Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
NIH Grants & Funding for Hereditary Neuropathy With Liability to Pressure Palsies | Kisho | Kisho
Cross-referencing NIH grants against published research and clinical trials to identify funding-evidence gaps for Hereditary Neuropathy With Liability to Pressure Palsies. Strongest funded area: Basic Science. Largest gap: Epidemiology / Natural History.
Clinical ResearchTrials Active, No NIH Grants
1 clinical trial registered but no NIH-funded clinical or translational research grants found for hereditary neuropathy with liability to pressure palsies. Trials may be industry-sponsored or funded through non-NIH sources.
Epidemiology / Natural HistoryPublished, Not NIH-Funded
15 publications in Case Report / Case Series but no NIH-funded grants found in Epidemiology / Natural History for hereditary neuropathy with liability to pressure palsies. Existing research activity suggests this may be a viable area for grant applications.
Epidemiology / Natural HistoryPublished, Not NIH-Funded
6 publications in Epidemiology / Natural History but no NIH-funded grants found in Epidemiology / Natural History for hereditary neuropathy with liability to pressure palsies. Existing research activity suggests this may be a viable area for grant applications.
Adjacent Research(1 grant)
These grants mention Hereditary Neuropathy With Liability to Pressure Palsies as part of broader research but are not primarily focused on this disease. They are not included in the funding totals above.
Other(1)
OtherR21Completed
Targeting the PMP22 Protein to Develop Leads Against Charcot-Marie-Tooth Disease
